Numaferm, a Düsseldorf, Germany-based specialist in the biotechnological production of peptides, received a minority investment in the one-digit million-euro range.
Backers included Evonik, High-Tech Gründerfonds, Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund.
The company intends to use the funds to drive forward technological development and get the first products to market maturity.
Co-founded at the start of 2017 by Christian Schwarz, managing director, as a spin-off of Heinrich Heine University Düsseldorf, Numaferm has developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs.
The company offers its technology, related R&D services and a peptide catalogue focusing on pharmaceutical, antimicrobial and adhesives peptides.